Physiopathology of somatolactotroph cells: from transduction mechanisms to cotargeting therapy. (Q37851164)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21388404 AND SRC:MED&resulttype=core&format=json

25 January 2020

review article

1 reference

title

Physiopathology of somatolactotroph cells: from transduction mechanisms to cotargeting therapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21388404 AND SRC:MED&resulttype=core&format=json

25 January 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21388404 AND SRC:MED&resulttype=core&format=json

25 January 2020

Corinne Gerard

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21388404 AND SRC:MED&resulttype=core&format=json

25 January 2020

Alexandru Saveanu

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21388404 AND SRC:MED&resulttype=core&format=json

25 January 2020

Anne Barlier

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21388404 AND SRC:MED&resulttype=core&format=json

25 January 2020

author name string

Alain Enjalbert

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21388404 AND SRC:MED&resulttype=core&format=json

25 January 2020

language of work or name

English

0 references

publication date

1 March 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21388404 AND SRC:MED&resulttype=core&format=json

Annals of the New York Academy of Sciences

25 January 2020

number of pages

11

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21388404 AND SRC:MED&resulttype=core&format=json

25 January 2020

volume

1220

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21388404 AND SRC:MED&resulttype=core&format=json

25 January 2020

page(s)

60-70

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21388404 AND SRC:MED&resulttype=core&format=json

Hormonal signaling and pituitary adenomas.

25 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05924.X

Vasoactive intestinal polypeptide and pituitary adenylate cyclase-activating polypeptides stimulate mitogen-activated protein kinase in the pituitary cell line GH4C1 by a 3',5'-cyclic adenosine monophosphate pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05924.X

Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05924.X

Stimulation of prolactin release by vasoactive intestinal peptide (VIP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05924.X

Crosstalk between cAMP and MAP kinase signaling in the regulation of cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05924.X

Growth hormone-releasing factor stimulates proliferation of somatotrophs in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05924.X

Stimulation of Adenosine 3′,5′-Monophosphate Production by Growth Hormone-Releasing Factor and Its Inhibition by Somatostatin in Anterior Pituitary Cellsin Vitro*

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05924.X

GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05924.X

G protein mutations in endocrine diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05924.X

G protein oncogenes in pituitary tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05924.X

GH3 cells expressing constitutively active Gs alpha (Q227L) show enhanced hormone secretion and proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05924.X

Signalling pathway alterations in pituitary adenomas: involvement of Gsalpha, cAMP and mitogen-activated protein kinases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05924.X

Relevant cAMP-specific phosphodiesterase isoforms in human pituitary: effect of Gs(alpha) mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05924.X

Effect of gsp oncogene on somatostatin receptor subtype 1 and 2 mRNA levels in GHRH-responsive GH3 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05924.X

Gs alpha overexpression and loss of Gs alpha imprinting in human somatotroph adenomas: association with tumor size and response to pharmacologic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05924.X

The cyclic adenosine 3',5'-monophosphate-responsive factor CREB is constitutively activated in human somatotroph adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05924.X

Specificity in the cAMP/PKA signaling pathway. Differential expression,regulation, and subcellular localization of subunits of PKA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05924.X

Carney complex: pathology and molecular genetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05924.X

Proliferation of transformed somatotroph cells related to low or absent expression of protein kinase a regulatory subunit 1A protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05924.X

Evidence that PKA activity is constitutively activated in human GH-secreting adenoma cells in a patient with Carney complex harbouring a PRKAR1A mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05924.X

MAP kinases and the control of nuclear events

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05924.X

MAP kinase signalling pathways in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05924.X

Rap1 signalling: adhering to new models

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05924.X

How MAP kinases are regulated

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05924.X

G-protein-coupled receptors and signaling networks: emerging paradigms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05924.X

Pituitary adenylate cyclase-activating polypeptide regulates prolactin promoter activity via a protein kinase A-mediated pathway that is independent of the transcriptional pathway employed by thyrotropin-releasing hormone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05924.X

A role for the mitogen-activated protein kinase in mediating the ability of thyrotropin-releasing hormone to stimulate the prolactin promoter.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05924.X

Differential regulation of pituitary hormone secretion and gene expression by thyrotropin-releasing hormone. A role for mitogen-activated protein kinase signaling cascade in rat pituitary GH3 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05924.X

Effects of hypothalamic neuropeptides on extracellular signal-regulated kinase (ERK1 and ERK2) cascade in human tumoral pituitary cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05924.X

Activation of RAF/MEK/ERK and PI3K/AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05924.X

cAMP activates MAP kinase and Elk-1 through a B-Raf- and Rap1-dependent pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05924.X

Differential Involvement of the Ras and Rap1 Small GTPases in Vasoactive Intestinal and Pituitary Adenylyl Cyclase Activating Polypeptides Control of the Prolactin Gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05924.X

Conditional overexpression of the wild-type Gs alpha as the gsp oncogene initiates chronic extracellularly regulated kinase 1/2 activation and hormone hypersecretion in pituitary cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05924.X

IGF-I inhibits apoptosis through the activation of the phosphatidylinositol 3-kinase/Akt pathway in pituitary cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05924.X

Targeting MAPK (Ras/ERK) and PI3K/Akt pathways in pituitary tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05924.X

The PTEN-PI3K pathway: of feedbacks and cross-talks

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05924.X

Ras, PI(3)K and mTOR signalling controls tumour cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05924.X

The molecular biology of pituitary tumors: a personal perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05924.X

Regulation of the RAP1/RAF-1/extracellularly regulated kinase-1/2 cascade and prolactin release by the phosphoinositide 3-kinase/AKT pathway in pituitary cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05924.X

Pituitary tumours: acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05924.X

A consensus on criteria for cure of acromegaly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05924.X

Somatostatin Receptors in Pituitary and Development of Somatostatin Receptor Subtype-Selective Analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05924.X

Relevance of coexpression of somatostatin and dopamine D2 receptors in pituitary adenomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05924.X

The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05924.X

Octreotide promotes apoptosis in human somatotroph tumor cells by activating somatostatin receptor type 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05924.X

sst2 Somatostatin receptor inhibits cell proliferation through Ras-, Rap1-, and B-Raf-dependent ERK2 activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05924.X

Pituitary somatostatin receptor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05924.X

Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05924.X

Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05924.X

Transcriptional activation of the mixed lineage leukemia-p27Kip1 pathway by a somatostatin analogue

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05924.X

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05924.X

Targeting cancer with small molecule kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05924.X

Activators and target genes of Rel/NF-kappaB transcription factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05924.X

Inhibition of NFkappaB reduces cellular viability in GH3 pituitary adenoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05924.X

Alpha1-adrenergic receptor antagonists: novel therapy for pituitary adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05924.X

Targeting pituitary tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05924.X

Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05924.X

The somatostatin analogue octreotide confers sensitivity to rapamycin treatment on pituitary tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05924.X

Selective loss of somatostatin receptor 2 in octreotide-resistant growth hormone-secreting adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05924.X

Gene therapy for pancreatic carcinoma: local and distant antitumor effects after somatostatin receptor sst2 gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05924.X

Characterization of the bystander effect of somatostatin receptor sst2 after in vivo gene transfer into human pancreatic cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05924.X

Somatostatin receptor sst2 decreases cell viability and hormonal hypersecretion and reverses octreotide resistance of human pituitary adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05924.X

Constitutive somatostatin receptor activity determines tonic pituitary cell response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05924.X

Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05924.X

Functional association of somatostatin receptor subtypes 2 and 5 in inhibiting human growth hormone secretion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05924.X

A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05924.X

Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05924.X

Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05924.X

Heterooligomerization of human dopamine receptor 2 and somatostatin receptor 2 Co-immunoprecipitation and fluorescence resonance energy transfer analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05924.X

Dopamine D2 receptor gene expression in human adenohypophysial adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05924.X

Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05924.X

Pituitary tumours: the sst/D2 receptors as molecular targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05924.X

Combined inhibition of MEK and mammalian target of rapamycin abolishes phosphorylation of cyclin-dependent kinase 4 in glioblastoma cell lines and prevents their proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05924.X

Altered Gs and adenylate cyclase activity in human GH-secreting pituitary adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05924.X

10.1111/J.1749-6632.2010.05924.X

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21388404 AND SRC:MED&resulttype=core&format=json

25 January 2020

1 reference